Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 13, 2016
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - February 13, 2016

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

2/13/16 - "Genetically Detoxified Pertussis That Maintains Intrinsic Adjuvant Activity" in Patent Application Approval Process (USPTO 20160015806)
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week A patent application by the inventor Kapre, Subhash V., filed on July 15, 2015, was made available online on January 28, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a company o
2/13/16 - Blend Therapeutics Secures $38 Million in Series C Financing led by Novo A/S and NEA and Changes Name to Tarveda Therapeutics
By a News Reporter-Staff News Editor at Investment Weekly News Tarveda Therapeutics, Inc., formerly Blend Therapeutics, announced that it has secured $38 million in Series C financing co-led by new investor Novo A/S and existing investor New Enterprise Associates. The company also announced the change of its corporate brand to clearly highlight t
2/13/16 - BRIEF: British regulators fine GSK $54.5M [The Philadelphia Inquirer]
Feb. 12 GlaxoSmithKline, with major U.S. operations in the Philadelphia area, was fined $54.5 million, or 37.6 million pounds, Friday by a British competition authority for allegedly preventing less-expensive generic versions of its anti-depressant drug Seroxat from entering the market. GlaxoSmithKline has commercial operations primarily for vacc
2/13/16 - COmpETiTiON fiNE ; COmpANiES TODAY [Newcastle Journal (England)]
The fine was handed down by the Competition and Markets Authority which said Glaxo made more than Pounds 50 m of payments to companies making cheaper generic versions of its anti-depressant Seroxat to delay them coming to market. Seroxat is Glaxo's branded paroxetine anti-depressant treatment. The CMA said the "pay-for-delay agreements" Glaxo struc
2/13/16 - Pharmaceutical industry self-regulation of off-label drug promotion in the UK
By a News Reporter-Staff News Editor at Marketing Weekly News The UK's self-regulatory approach to preventing pharmaceutical companies from promoting off-label use of their drugs detects mainly high-visibility promotional activity such as print advertising, according to a document analysis of off-label promotion rulings published this week in...
2/12/16 - "Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2015" Now Available at Fast Market Research
Fast Market Research announces the availability of the new Global Markets Direct report, "Glioblastoma Multiforme- Pipeline Review, H2 2015", on their comprehensive research portalBoston, MA 02/12/2016 Global Markets Direct's,' Glioblastoma Multiforme- Pipeline Review, H2 2015', provides an overview of the Glioblastoma Multiforme' s therapeut
2/12/16 - "Stable Dosage Forms of Imatinib Mesylate" in Patent Application Approval Process (USPTO 20160015708)
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors KOCHHAR, Ravi; RAMESH, Annavarapu; VASIREDDY, Suneel Kumar; SANDAL, Roshan Lal, filed on February 15, 2013, was made available online on January 28, 2016, according to news reporting originating from Washington, D.C., by NewsRx correspondents. Currently, it is
2/12/16 - 11 companies approved for sale of latest hepatitis C drug: Saira
Minister of State for Health Services, Regulations and Coordination Saira Afzal Tarar Thursday said that Drug Regulatory Authority of Pakistan had approved 11 new companies for sale of generic version of a new miracle drug Sofosbuvir, the latest therapy available in the world for hepatitis C. Saira Tarar said prevalence of hepatitis C in Pakistan w
2/12/16 - 11 COMPANIES APPROVED FOR SALE OF LATEST HEPATITIS C DRUG: SAIRA [Pakistan Observer]
Minister of State for Health Services, Regulations and Coordination Saira Afzal Tarar Thursday said that Drug Regulatory Authority of Pakistan had approved 11 new companies for sale of generic version of a new miracle drug Sofosbuvir, the latest therapy available in the world for hepatitis C. Addressing a press conference here Thursday, she said DR
2/12/16 - 9 firms allowed to sell cheaper hepatitis C pills
The Drug Regulatory Authority of Pakistan has authorised 11 pharmaceutical companies for sale of generic version of new drug Sofosbuvir which will be available for Rs5, 868 for Hepatitis C patients in the country. Minister of National Health Services, Regulation and Coordination Saira Afzal Tarar said this while addressing a press conference here o
2/12/16 - ABPI - Cancer Drugs Fund consultation - an opportunity to introduce a sustainable, affordable solution that benefits patients and the economy
Release date- 11022016- As the consultation on the way forward for the Cancer Drugs Fund closes, the Association of the British Pharmaceutical Industry urges the government to seize the opportunity and transform the way cancer medicines are assessed by the National Institute for Health and Care Excellence and commissioned and funded by NHS England.
2/12/16 - Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor [Saudi Press Agency (Saudi Arabia)]
-Achillion Pharmaceuticals, Inc. today announced the initiation of a phase 1 study with ACH-4471, the Companys first orally-administered, highly potent and specific small molecule that has been shown to inhibit complement factor D. The phase 1 study is being conducted in healthy volunteers and is evaluating single ascending doses of ACH-4471 to ass
2/12/16 - Aegerion Pharmaceuticals Announces Reduction in Workforce as Part of Cost Reduction Plan [Saudi Press Agency (Saudi Arabia)]
-Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that it is reducing approximately 25% percent of its global workforce. This reduction in force is part of a broad program taken by Aegerion to...
2/12/16 - Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Guidance for Industry on Formal Meetings With...
Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Guidance for Industry on Formal Meetings With Sponsors and Applicants for Prescription Drug User Fee Act Products. SUMMARY: The Food and Drug Administration is announcing that a collection of information entitled "Guidance for Industry on Formal...
2/12/16 - Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Labeling of Certain Beers Subject to the Labeling...
Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Labeling of Certain Beers Subject to the Labeling Jurisdiction of the Food and Drug Administration. SUMMARY: The Food and Drug Administration is announcing that a collection of information entitled "Labeling of Certain Beers Subject to the Labeling..
2/12/16 - Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Registration of Producers of Drugs and Listing of...
Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Registration of Producers of Drugs and Listing of Drugs in Commercial Distribution. SUMMARY: The Food and Drug Administration is announcing that a collection of information entitled "Registration of Producers of Drugs and Listing of Drugs in Commerci
2/12/16 - Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Request for Samples and Protocols
SUMMARY: The Food and Drug Administration is announcing that a collection of information entitled "Request for Samples and Protocols" has been approved by the Office of Management and Budget under the Paperwork Reduction Act of 1995.. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville
2/12/16 - Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) to Ring The Nasdaq Stock Market Closing Bell
What: Aralez Pharmaceuticals Inc., a global speciality pharmaceutical company, will visit the Nasdaq MarketSite in Times Square. Where: Nasdaq MarketSite 4 Times Square 43 rd& Broadway Broadcast Studio. Gal 3 C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/ 4 SR 13.235 DR 18.295411 MOD 4: 2: 0 DVBS QPSK.
2/12/16 - Aralez to Ring Closing Bell at Nasdaq on February 16, 2016
Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced the Company will ring the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York at 4:00 p.m. ET on Tuesday, February 16, 2016 to celebrate the formation of Aralez. Chief Executive Officer, Adrian Adams, will perform the honorary bell ringing c
2/12/16 - Ashland's manufacturing plant in Calvert City, Kentucky, is first U. S. excipient facility to receive EXCiPACT certification
Release date- 11022016- WILMINGTON, Delaware- Ashland today announced that its Calvert City, Kentucky, facility has earned EXCiPACTTM certification for Good Manufacturing Practice. Since both the U.S. Food and Drug Administration and the European Medicines Agency require that excipient suppliers be qualified by drug producers, EXCiPACTTM certificat
2/12/16 - Benchmarking Clinical Trial Strategies for Success in a Global Marketplace
Clinical Affairs leaders at pharmaceutical organizations are looking to either start or increase their clinical presence in emerging areas of the world. While some companies have conducted a significant number of clinical trials in emerging regions, others lag in their clinical activity in countries such as India and China. While there are many..
2/12/16 - Biofrontera AG: Pivotal Phase III Data Demonstrate Significant Efficacy and Excellent Safety for BF-200 ALA Treatment of Superficial Skin Cancer [Arab News (Saudi Arabia)]
-Biofrontera AG, the specialist for sun-induced skin cancer, presents data from three pivotal Phase III trials for its lead drug candidate BF-200 ALA at the 14th Annual South Beach Symposium. The results are being presented in a poster on display February 11-14 and will be highlighted during two oral presentations on Friday, February 12 by two memb
2/12/16 - Bionor Q4 and Full Year 2015 Interim Financial Report
Bionor Pharma ASA Interim Financial Report 1 January- 31 December 2015 Unaudited Oslo, 12 February 2016 HIGHLIGHTS Q4 2015 In the fourth quarter of 2015, Bionor accelerated the company's revitalization by executing the updated business strategy and development plans presented at the company's Capital Markets Day in October 2015. *21 December, Biono
2/12/16 - Breast Cancer - Pipeline Review, H2 2015 - New Market Study Published
Fast Market Research announces the availability of the new Global Markets Direct report, "Breast Cancer- Pipeline Review, H2 2015", on their comprehensive research portalBoston, MA 02/12/2016 Global Markets Direct's,' Breast Cancer- Pipeline Review, H2 2015', provides an overview of the Breast Cancer's therapeutic pipeline. This report provid
2/12/16 - BRIEF: British regulators fine GSK $54.5M [The Philadelphia Inquirer]
Feb. 12 GlaxoSmithKline, with major U.S. operations in the Philadelphia area, was fined $54.5 million, or 37.6 million pounds, Friday by a British competition authority for allegedly preventing less-expensive generic versions of its anti-depressant drug Seroxat from entering the market. GlaxoSmithKline has commercial operations primarily for vacc
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415